2. Search Result
Search Result
Results for "

ventricular systolic

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-159821
    Ulacamten

    CK-4021586; CK-586

    		 Myosin Cardiovascular Disease
    Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC50 of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .
    Ulacamten
  • HY-174374
    Topobexin

    		Topoisomerase Cardiovascular Disease
    Topobexin is a TOP2B-selective inhibitor with IC50 values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity .
    Topobexin
  • HY-148804
    Vemtoberant

    APD418

    		 Adrenergic Receptor Cardiovascular Disease
    Vemtoberant is a β3-adrenergic receptor inhibitor with a human Ki of 8.2 nM, and exhibits 400- to 600-fold selectivity over human β1-AR and β2-AR. Vemtoberant attenuates β3-AR-mediated cardiac inhibition. Vemtoberant can be used for the research of systolic heart failure .
    Vemtoberant
  • HY-149662
    TMDJ-035

    		Calcium Channel ATP Synthase Myosin Cardiovascular Disease
    TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC50 of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca 2+ transients. TMDJ-035 decreases ATP content and intracellular Ca 2+ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .
    TMDJ-035
  • HY-173517
    NHE-1-IN-2

    		Na+/H+ Exchanger (NHE) Neurological Disease
    NHE-1-IN-2 (compound 7g) is a potent NHE-1 inhibitor with an IC50 of 0.78 μM. NHE-1-IN-2 alleviates left ventricular systolic dysfunction in mice model of heart failure .
    NHE-1-IN-2
  • HY-129782
    SC-55858

    		SOD Cardiovascular Disease
    SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs .
    SC-55858
  • HY-120257
    IDN-1965

    		Caspase Apoptosis Cardiovascular Disease
    IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation .
    IDN-1965
  • HY-106458
    Niludipine

    Bay a 7168

    		 Calcium Channel Cardiovascular Disease
    Niludipine (Bay a 7168) is an orally active calcium channel blocker and vasodilator with antihypertensive effects. Niludipine can improve early fatal ventricular arrhythmias induced by acute myocardial ischemia in rats. Niludipine can reduce left ventricular systolic and diastolic loads during pacing-induced angina pectoris. Niludipine can be used in the research of cardiovascular diseases such as coronary heart disease and myocardial ischemia .
    Niludipine
  • HY-160475
    AD-9308

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Autophagy Cardiovascular Disease Metabolic Disease
    AD-9308 is a highly selective and orally active ALDH2 activator. AD-9308 activates ALDH2 to promote the clearance of 4-HNE, inhibiting myocardial fibrosis, inflammation and cell apoptosis. AD-9308 improves mitochondrial function, sarcoplasmic reticulum/ endoplasmic reticulum calcium transport and regulates autophagy, restoring intracellular homeostasis. AD-9308 improves the diastolic and systolic function of the heart in diabetic mice and reverses ventricular mal-reconstruction. AD-9308 can be used for the study of diabetic cardiomyopathy .
    AD-9308

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: